NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market
NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts.
Neogenomics Inc (NEO)
Market is closed
Sector: Services-Testing Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 101,381,000 | $87,060,934 | 2.98% | ||
| 2. | Greenhouse Funds Joe Milano | 7,431,147 | $54,321,685 | +58% | 2.24% |
| 3. | Millennium Management Israel Englander | 3,316,808 | $24,245,866 | -51% | 0.01% |
| 4. | 26,822,000 | $23,167,503 | +88% | 1.32% | |
| 5. | Deerfield Management James E. Flynn | 2,148,000 | $15,701,880 | 0.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.62 | 20,000 | $112,322.00 | 188,332 | 2025-08-06 | Filing | |
| $5.58 | 17,900 | $99,953.60 | 38,066 | 2025-08-06 | Filing | |
| $7.60 | 5,000 | $38,000.00 | 5,000 | 2025-05-27 | Filing | |
| $8.58 | 5,700 | $48,894.60 | 108,280 | 2025-05-12 | Filing | |
| $8.14 | 7,000 | $56,974.40 | 7,000 | 2025-05-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.36 | 5,175 | $79,475.06 | 37,129 | 2024-11-15 | Filing | |
| $16.05 | 1,040 | $16,695.43 | 43,813 | 2024-08-15 | Filing | |
| $15.74 | 1,049 | $16,511.26 | 44,867 | 2024-05-15 | Filing | |
| $15.97 | 6,112 | $97,578.69 | 50,062 | 2024-03-04 | Filing | |
| $14.96 | 2,587 | $38,712.90 | 34,866 | 2024-02-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,424,588 | $141,993,738 | 0% | |
| 2. | 14,130,761 | $103,295,863 | 0% | |
| 3. | 92,722,000 | $79,673,310 | 1.07% | |
| 4. | 6,846,432 | $50,047,418 | 6.49% | |
| 5. | 44,576,000 | $38,056,337 | 0.23% |
News See All
Top 10 Medical AI Companies to Buy According to Analysts
Artificial intelligence is transforming medical sciences in ways not seen before.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the NeoGenomics Second Quarter 2025 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Here’s Why NeoGenomics (NEO) Sold Off in Q1
Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript
Operator: Greetings and welcome to the NeoGenomics First Quarter 2025 Conference Call.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
20 Most Profitable Stocks of the Last 20 Years
The stock market has a long history of generating wealth for investors. While past performance doesn't guarantee future results, studying successful companies can provide valuable insights.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03.
Billionaire Hedge Funds
